Therapeutic Potential of Metabolites from Lactobacillus rhamnosus and Mare’s Milk in the Treatment of Dysbiosis

Abstract

Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis. Agents modulating microbial dysbiosis caused by colitis can help in the remission of this disease. The current study describes the potential therapeutic effects of active metabolites from Lactobacillus rhamnosus and mare’s milk which have potential therapeutic values on the intestinal microbiota and proinflammatory cytokines. The analysis of the V1-V3 16S rDNA site revealed significant changes in the intestinal microbiome composition before and after treatment in the treated group compared to the positive control group that was treated with 5-aminosalicylic acid (5-ASA). So the effect of the study product on dextran sulfate sodium-induced dysbiosis was shown to be more potent than the positive control, 5-ASA. The level of proinflammatory cytokines also decreased under the influence of a biological product.

Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022

“…Additionally, combinations of L. rhamnosus with other agents have also been studied. Samat Kozhakhmetov et al ( Kozhakhmetov et al, 2022 ) mixed L. rhamnosus with food-grade horse milk and administered the combination to mice with DSS-induced colitis, resulting in a significant improvement in UC symptoms. Similarly, L. rhamnosus 1.0320 with inulin and LGG combined with targose significantly improved symptoms of colitis in mice ( Son et al, 2019 ; Liu et al, 2020 ).…”